Login Register Cart 0
Mini-Review Article

Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis

Author(s): Gaurav Doshi* and Ami Thakkar

Volume 22, Issue 7, 2021

Published on: 27 October, 2020

Page: [803 - 815] Pages: 13

DOI: 10.2174/1389450121666201027124625

Price: $65

Abstract

Rheumatoid Arthritis (RA) is a systemic, chronic, autoimmune, inflammatory disorder that affects both large and small synovial joints in a symmetric pattern. RA initiates as painful inflammation of the joints leading to stiffness of joint, joint destruction and further worsens the condition causing permanent irreversible damage to the joints, making them physically disabled. Across the globe, there are around 1.2 million cases of RA reported. Inspite of various available therapeutic and pharmacological agents against RA, none of the treatments assure complete cure. Understanding the in depth-role of cytokines and interleukins in the disease pathogenesis of RA could help in exploiting them for developing novel therapeutic strategies against RA. This review provides insights into the pathogenesis of RA and gives a brief overview of cytokines, which play an important role in the progression of the disease. We have also discussed the possible role of interleukins in the context of RA, which could help future researchers to explore them for identifying new therapeutic agents.

Keywords: Rheumatoid arthritis, cytokines, interleukins, TNF-α, IL-1, IL-17.

« Previous Next »
Graphical Abstract

[1]
Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018; 4: 18001.
[2]
Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clin Rheumatol 2019; 38(11): 2967-76.
[http://dx.doi.org/10.1007/s10067-019-04684-1] [PMID: 31520227]
[3]
Handa R, Rao URK, Lewis JFM, Rambhad G, Shiff S, Ghia CJ. Literature review of rheumatoid arthritis in India. Int J Rheum Dis 2016; 19(5): 440-51.
[http://dx.doi.org/10.1111/1756-185X.12621] [PMID: 26171649]
[4]
Rudan I, Sidhu S, Papana A, et al. Global Health Epidemiology Reference Group (GHERG). Prevalence of rheumatoid arthritis in low- and middle-income countries: A systematic review and analysis. J Glob Health 2015; 5(1): 010409.
[PMID: 25969732]
[5]
WHO | Global Health Estimates https://www.who.int/healthinfo/global_burden_disease/en/
[6]
Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006; 36(3): 182-8.
[http://dx.doi.org/10.1016/j.semarthrit.2006.08.006] [PMID: 17045630]
[7]
Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44(3): 291-6.
[http://dx.doi.org/10.1038/ng.1076] [PMID: 22286218]
[8]
Ting YT, Petersen J, Ramarathinam SH, et al. The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis. J Biol Chem 2018; 293(9): 3236-51.
[http://dx.doi.org/10.1074/jbc.RA117.001013] [PMID: 29317506]
[9]
Hedström AK, Rönnelid J, Klareskog L, Alfredsson L. Complex relationships of smoking, hla-drb1 genes, and serologic profiles in patients with early rheumatoid arthritis: update from a swedish population-based case-control study. Arthritis Rheumatol 2019; 71(9): 1504-11.
[http://dx.doi.org/10.1002/art.40852] [PMID: 30742363]
[10]
Manasson J, Blank RB, Scher JU. The microbiome in rheumatology: Where are we and where should we go? Ann Rheum Dis 2020; 79(6): 727-33.
[PMID: 32332073]
[11]
Dar L, Tiosano S, Watad A, et al. Are obesity and rheumatoid arthritis interrelated? Int J Clin Pract
[http://dx.doi.org/10.1111/ijcp.13045]
[12]
Farquhar H, Vassallo R, Edwards AL, Matteson EL. Pulmonary complications of rheumatoid arthritis. Semin Respir Crit Care Med 2019; 40(2): 194-207.
[http://dx.doi.org/10.1055/s-0039-1683995] [PMID: 31137060]
[13]
ACR Diagnostic Guidelines https://www.hopkinsarthritis.org/physician-corner/education/arthritis-education-diagnostic-guidelines/#class_rheum
[14]
Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 2019; 78(11): 1463-71.
[http://dx.doi.org/10.1136/annrheumdis-2019-215920] [PMID: 31511227]
[15]
Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid arthritis: A brief overview of the treatment. Med Princ Pract 2018; 27(6): 501-7.
[http://dx.doi.org/10.1159/000493390] [PMID: 30173215]
[16]
Sizova L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol 2008; 66(2): 173-8.
[http://dx.doi.org/10.1111/j.1365-2125.2008.03222.x] [PMID: 18537958]
[17]
Jin Y, Desai RJ, Liu J, et al. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Res Ther 2017; 15: 159.
[http://dx.doi.org/10.1186/s13075-017-1366-1]
[18]
Benjamin O, Bansal P, Goyal A, et al. Disease Modifying Anti-Rheumatic Drugs (DMARD) https://www.ncbi.nlm.nih.gov/books/NBK507863/2019.
[19]
Kean WF, Buchanan WW. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology 2005; 13(4): 343-70.
[http://dx.doi.org/10.1163/156856005774415565] [PMID: 16354389]
[20]
Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013; 15(Suppl. 3): S2.
[http://dx.doi.org/10.1186/ar4174] [PMID: 24267197]
[21]
RA and Corticosteroids: What is the Role of Steroids in Arthritis Treatment? RheumatoidArthritis https://www.rheumatoidarthritis.org/treatment/medications/corticosteroids/
[22]
Dennison EM, Cooper C. Corticosteroids in rheumatoid arthritis. BMJ 1998; 316(7134): 789-90.
[http://dx.doi.org/10.1136/bmj.316.7134.789] [PMID: 9549442]
[23]
Gøtzsche PC, Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998; 316(7134): 811-8.
[http://dx.doi.org/10.1136/bmj.316.7134.811] [PMID: 9549450]
[24]
Raza K, Holers VM, Gerlag D. Nomenclature for the Phases of the Development of Rheumatoid Arthritis. Clin Ther 2019; 41(7): 1279-85.
[http://dx.doi.org/10.1016/j.clinthera.2019.04.013] [PMID: 31196657]
[25]
Tracy A, Buckley CD, Raza K. Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease start? Semin Immunopathol 2017; 39(4): 423-35.
[http://dx.doi.org/10.1007/s00281-017-0620-6] [PMID: 28337522]
[26]
Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Research 2018; 15(6)
[27]
van de Sande MGH, de Hair MJH, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011; 70(5): 772-7.
[http://dx.doi.org/10.1136/ard.2010.139527] [PMID: 21177292]
[28]
Catrina AI, Svensson CI, Malmström V, Schett G, Klareskog L. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol 2017; 13(2): 79-86.
[http://dx.doi.org/10.1038/nrrheum.2016.200] [PMID: 27974851]
[29]
Wigerblad G, Bas DB, Fernades-Cerqueira C, et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis 2016; 75(4): 730-8.
[http://dx.doi.org/10.1136/annrheumdis-2015-208094] [PMID: 26613766]
[30]
Steffen U, Schett G, Bozec A. How autoantibodies regulate osteoclast induced bone loss in rheumatoid arthritis. Front Immunol 2019; 10: 1483.
[http://dx.doi.org/10.3389/fimmu.2019.01483] [PMID: 31333647]
[31]
Sudoł-Szopińska I, Kontny E, Maśliński W, et al. The pathogenesis of rheumatoid arthritis in radiological studies. Part I: Formation of inflammatory infiltrates within the synovial membrane. J Ultrason 2012; 12(49): 202-13.
[http://dx.doi.org/10.15557/JoU.2012.0007] [PMID: 26673660]
[32]
Veale DJ, Orr C, Fearon U. Cellular and molecular perspectives in rheumatoid arthritis. Semin Immunopathol 2017; 39(4): 343-54.
[http://dx.doi.org/10.1007/s00281-017-0633-1] [PMID: 28508153]
[33]
L. Ferreira V, H.L. Borba H, de F. Bonetti A, et al. Cytokines and Interferons: Types and Functions.Autoantibodies and Cytokines. IntechOpen 2019.
[34]
Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to Interleukin 40. J Interferon Cytokine Res 2018; 38(10): 423-39.
[http://dx.doi.org/10.1089/jir.2018.0089] [PMID: 30328794]
[35]
Stenken JA, Poschenrieder AJ. Bioanalytical chemistry of cytokines--a review. Anal Chim Acta 2015; 853: 95-115.
[http://dx.doi.org/10.1016/j.aca.2014.10.009] [PMID: 25467452]
[36]
Floege J, Lüscher B, Müller-Newen G. Cytokines and inflammation. Eur J Cell Biol 2012; 91(6-7): 427.
[http://dx.doi.org/10.1016/j.ejcb.2012.01.003] [PMID: 22365147]
[37]
Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: Role of inflammation triggers and cytokines. Front Immunol 2018; 9: 586.
[http://dx.doi.org/10.3389/fimmu.2018.00586] [PMID: 29686666]
[38]
Farrugia M, Baron B. The role of TNF-α in rheumatoid arthritis: a focus on regulatory T cells. J Clin Transl Res 2016; 2(3): 84-90.
[http://dx.doi.org/10.18053/jctres.02.201603.005] [PMID: 30873466]
[39]
Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol 2016; 12(1): 14-24.
[http://dx.doi.org/10.1038/nrrheum.2016.166] [PMID: 26656658]
[40]
Kaneko N, Kurata M, Yamamoto T, et al. The role of interleukin-1 in general pathology. Inflamm Regen 2019; 39: 12.
[http://dx.doi.org/10.1186/s41232-019-0101-5]
[41]
Favalli EG. Understanding the role of interleukin-6 ( il-6 ) in the joint and beyond : a comprehensive review of il-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther 2020; 7(3): 473-516.
[42]
Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012; 8(9): 1237-47.
[http://dx.doi.org/10.7150/ijbs.4989] [PMID: 23136552]
[43]
Churchman SM, El-Jawhari JJ, Burska AN, et al. Modulation of peripheral T-cell function by interleukin-7 in rheumatoid arthritis. Arthritis Res Ther 2014; 16(6): 511.
[44]
Lundström W, Fewkes NM, Mackall CL. IL-7 in human health and disease. Semin Immunol 2012; 24(3): 218-24.
[http://dx.doi.org/10.1016/j.smim.2012.02.005] [PMID: 22410365]
[45]
Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The role of il-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm 2017; 2017: 3908061.
[http://dx.doi.org/10.1155/2017/3908061] [PMID: 28316374]
[46]
Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 2015; 11(7): 415-29.
[http://dx.doi.org/10.1038/nrrheum.2015.53] [PMID: 25907700]
[47]
Yago T, Nanke Y, Kawamoto M, Kobashigawa T, Yamanaka H, Kotake S. IL-35 inhibits human osteoclastogenesis from monocytes induced by receptor-activator of NF-κB ligand. Cent Eur J Immunol 2018; 43(2): 148-54.
[http://dx.doi.org/10.5114/ceji.2018.77384] [PMID: 30135626]
[48]
Li Y, Yao L, Liu S, et al. Correlation between serum IL-35 Levels and bone loss in postmenopausal women with rheumatoid arthritis. Mediators Inflamm 2019; 20199139145
[http://dx.doi.org/10.1155/2019/9139145] [PMID: 31534439]
[49]
Radner H, Aletaha D. Anti-TNF Therapie in der Rheumatoiden Arthritis – ein Überblick. Wien Med Wochenschr 2015; 165: 3-9.
[http://dx.doi.org/10.1007/s10354-015-0344-y] [PMID: 25651945]
[50]
van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9(3): 164-72.
[http://dx.doi.org/10.1038/nrrheum.2013.4] [PMID: 23399692]
[51]
Ma X, Xu S. MA X. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 2013; 1(2): 177-84.
[http://dx.doi.org/10.3892/br.2012.42] [PMID: 24648915]
[52]
Chaabo K, Kirkham B. Rheumatoid Arthritis - Anti-TNF. Int Immunopharmacol 2015; 27(2): 180-4.
[http://dx.doi.org/10.1016/j.intimp.2015.04.051] [PMID: 25962818]
[53]
Bonovas S, Minozzi S, Lytras T, et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 2016; 15(sup1): 35-54.
[http://dx.doi.org/10.1080/14740338.2016.1238458] [PMID: 27924644]
[54]
Markus R, McBride HJ, Ramchandani M, et al. A review of the totality of evidence supporting the development of the first adalimumab biosimilar abp 501. Adv Ther 2019; 36(8): 1833-50.
[http://dx.doi.org/10.1007/s12325-019-00979-6] [PMID: 31183781]
[55]
Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases. Cytokine 2015; 76(1): 25-37.
[http://dx.doi.org/10.1016/j.cyto.2015.06.017] [PMID: 26185894]
[56]
Dayer J-M, Oliviero F, Punzi L. A Brief History of IL-1 and IL-1 Ra in Rheumatology. Front Pharmacol 2017; 8: 293.
[http://dx.doi.org/10.3389/fphar.2017.00293] [PMID: 28588495]
[57]
Kaneko N, Kurata M, Yamamoto T, Morikawa S, Masumoto J. The role of interleukin-1 in general pathology. Inflamm Regen 2019; 39: 12.
[http://dx.doi.org/10.1186/s41232-019-0101-5] [PMID: 31182982]
[58]
The role of interleukin 1 in the pathogenesis of rheumatoid arthritis https://pubmed.ncbi.nlm.nih.gov/3326690/
[59]
Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl 2): ii3-10.
[http://dx.doi.org/10.1093/rheumatology/keg326]
[60]
Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006; 20(5): 879-96.
[http://dx.doi.org/10.1016/j.berh.2006.06.004] [PMID: 16980212]
[61]
Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol 2019; 15(10): 612-32.
[http://dx.doi.org/10.1038/s41584-019-0277-8] [PMID: 31515542]
[62]
Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 2004; 26(12): 1960-75.
[http://dx.doi.org/10.1016/j.clinthera.2004.12.019] [PMID: 15823761]
[63]
Rondeau JM, Ramage P, Zurini M, Gram H. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs 2015; 7(6): 1151-60.
[http://dx.doi.org/10.1080/19420862.2015.1081323] [PMID: 26284424]
[64]
Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41(12): 2196-204.
[http://dx.doi.org/10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2] [PMID: 9870876]
[65]
Nuki G, Bresnihan B, Bear MB, McCabe D. European Group Of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(11): 2838-46.
[http://dx.doi.org/10.1002/art.10578] [PMID: 12428223]
[66]
Cohen SB, Woolley JM, Chan W. Anakinra 960180 Study Group. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 2003; 30(2): 225-31.
[PMID: 12563672]
[67]
Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(3): 614-24.
[http://dx.doi.org/10.1002/art.10141] [PMID: 11920396]
[68]
Cohen SB. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2004; 30(2): 365-80.
[http://dx.doi.org/10.1016/j.rdc.2004.01.005] [PMID: 15172046]
[69]
Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48(4): 927-34.
[http://dx.doi.org/10.1002/art.10870] [PMID: 12687534]
[70]
Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65(8): 1006-12.
[http://dx.doi.org/10.1136/ard.2005.048371] [PMID: 16396977]
[71]
Cardiel MH, Tak PP, Bensen W, et al. A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12(5): R192.
[72]
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813(5): 878-88.
[http://dx.doi.org/10.1016/j.bbamcr.2011.01.034] [PMID: 21296109]
[73]
Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014; 141(2): 125-39.
[http://dx.doi.org/10.1016/j.pharmthera.2013.09.004] [PMID: 24076269]
[74]
Kim GW, Lee NR, Pi RH, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res 2015; 38(5): 575-84.
[http://dx.doi.org/10.1007/s12272-015-0569-8] [PMID: 25648633]
[75]
Kaneshiro K, Sakai Y, Suzuki K, et al. Interleukin-6 and tumour necrosis factor-α cooperatively promote cell cycle regulators and proliferate rheumatoid arthritis fibroblast-like synovial cells. Scand J Rheumatol 2019; 48(5): 353-61.
[http://dx.doi.org/10.1080/03009742.2019.1602164] [PMID: 31631790]
[76]
Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012; 122(4): 143-59.
[http://dx.doi.org/10.1042/CS20110340] [PMID: 22029668]
[77]
Mitchell E, Jones G. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2016; 12(2): 103-14.
[http://dx.doi.org/10.1586/1744666X.2016.1127159] [PMID: 26629984]
[78]
Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother 2017; 13(9): 1972-88.
[http://dx.doi.org/10.1080/21645515.2017.1316909] [PMID: 28841363]
[79]
Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66(9): 1162-7.
[http://dx.doi.org/10.1136/ard.2006.068064] [PMID: 17485422]
[80]
Tanaka Y, Wada K, Takahashi Y, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther 2019; 21(1): 79-9.
[http://dx.doi.org/10.1186/s13075-019-1856-4] [PMID: 30894208]
[81]
Akashi K, Kondo M, Weissman IL. Role of interleukin-7 in T-cell development from hematopoietic stem cells. Immunol Rev 1998; 165: 13-28.
[http://dx.doi.org/10.1111/j.1600-065X.1998.tb01226.x] [PMID: 9850848]
[82]
Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11(5): 330-42.
[http://dx.doi.org/10.1038/nri2970] [PMID: 21508983]
[83]
Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol 2019; 20(12): 1584-93.
[http://dx.doi.org/10.1038/s41590-019-0479-x] [PMID: 31745336]
[84]
Churchman SM, Ponchel F. Interleukin-7 in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47(6): 753-9.
[http://dx.doi.org/10.1093/rheumatology/ken053] [PMID: 18356170]
[85]
Cai L, Xu H, Zhang H, Zhang L, Wang G, Nie H. Blockade of IL-7Rα alleviates collagen-induced arthritis via inhibiting Th1 cell differentiation and CD4+ T cell migration. Mol Immunol 2016; 79: 83-91.
[http://dx.doi.org/10.1016/j.molimm.2016.09.017] [PMID: 27736699]
[86]
Dooms H. Interleukin-7: Fuel for the autoimmune attack. J Autoimmun 2013; 45: 40-8.
[http://dx.doi.org/10.1016/j.jaut.2013.06.007] [PMID: 23831438]
[87]
Cutolo M. The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis 2013; 5(1): 3-11.
[http://dx.doi.org/10.1177/1759720X12470753] [PMID: 23515130]
[88]
Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal 2013; 25(12): 2335-47.
[http://dx.doi.org/10.1016/j.cellsig.2013.07.021] [PMID: 23917206]
[89]
Monin L, Gaffen SL. Interleukin 17 family cytokines: Signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol 2018; 10(4): a028522.
[90]
McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity 2019; 50(4): 892-906.
[http://dx.doi.org/10.1016/j.immuni.2019.03.021] [PMID: 30995505]
[91]
Robert M, Miossec P. IL-17 in rheumatoid arthritis and precision medicine: From synovitis expression to circulating bioactive levels. Frontiers in Medicine
[92]
Kunwar S, Dahal K, Sharma S. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatol Int 2016; 36(8): 1065-75.
[http://dx.doi.org/10.1007/s00296-016-3480-9] [PMID: 27105880]
[93]
Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 2008; 30(11): 1939-55.
[http://dx.doi.org/10.1016/j.clinthera.2008.11.007] [PMID: 19108784]
[94]
Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2(52): 52ra72.
[95]
Martin DA, Churchill M, Flores-Suarez LF, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013; 15(5): R164.
[96]
Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62(4): 929-39.
[http://dx.doi.org/10.1002/art.27334] [PMID: 20131262]
[97]
Guan SY, Leng RX, Khan MI, et al. Interleukin-35: a potential therapeutic agent for autoimmune diseases. Inflammation 2017; 40(1): 303-10.
[http://dx.doi.org/10.1007/s10753-016-0453-9] [PMID: 27696334]
[98]
Li Y, Yao L, Liu S, et al. Elevated serum IL-35 levels in rheumatoid arthritis are associated with disease activity. J Investig Med 2019; 67(3): 707-10.
[http://dx.doi.org/10.1136/jim-2018-000814] [PMID: 30659089]
[99]
Ye L, Wen Z, Li Y, et al. Interleukin-10 attenuation of collagen-induced arthritis is associated with suppression of interleukin-17 and retinoid-related orphan receptor γt production in macrophages and repression of classically activated macrophages. Arthritis Res Ther 2014; 16(2): R96.
[http://dx.doi.org/10.1186/ar4544] [PMID: 24742125]
[100]
Su LC, Liu XY, Huang AF, Xu WD. Emerging role of IL-35 in inflammatory autoimmune diseases. Autoimmun Rev 2018; 17(7): 665-73.
[http://dx.doi.org/10.1016/j.autrev.2018.01.017] [PMID: 29729445]
[101]
Bello RO, Chin VK, Abd Rachman Isnadi MF, et al. The role, involvement and function(S) of interleukin-35 and interleukin-37 in disease pathogenesis. International Journal of Molecular Sciences 2018; 19(4): 1149.
[102]
Ning X, Jian Z, Wang W. Low serum levels of interleukin 35 in patients with rheumatoid arthritis. Tohoku J Exp Med 2015; 237(2): 77-82.
[http://dx.doi.org/10.1620/tjem.237.77] [PMID: 26370008]
[103]
Šenolt L, Šumová B, Jandová R, et al. Interleukin 35 synovial fluid levels are associated with disease activity of rheumatoid arthritis. PLoS One 2015; 10(7): e0132674.

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy